What Pharma Gets Wrong About Compliance and How the Middle Office Can Fix It

Introduction

Pharmaceutical companies have made huge strides in adopting digital tools to support quality and compliance. In fact, global spending on pharma tech and digital transformation surpassed $60 billion in 2024 alone, with investments spanning eQMS, regulatory information management, LIMS, and digital manufacturing platforms. Yet, surprisingly, quality events, warning letters, and regulatory citations continue to rise. In the US, the FDA issued more than 190 warning letters to drug and biologics manufacturers in FY2024, 113 of which were inspection-based. The FDA issued over 1,100 Form 483 observations in 2023, with 561 related to stability program deficiencies, up from 510 in FY2023 and 215 in FY2021.

This contradiction between rising investment and increasing non-compliance points to a deeper problem: while the pharma industry has focused heavily on digitization, it has largely neglected the core operational layer where compliance either succeeds or fails.

The missing link? A connected, efficient Middle Office that ensures strategic compliance goals translate into day-to-day action.

Most Pharma Compliance Failures Are Operational, Not Strategic

Ask any quality leader in pharma and they’ll echo the same frustration: the intent to comply is strong, the policies exist, and the investments are being made. Yet, audits still uncover the same issues, year after year.

These include:

• Data integrity violations
• Incomplete investigations
• Uncontrolled changes
• Deviation records missing essential documentation

These are not failures of planning; they are failures of execution. According to the FDA’s analysis of common Form 483 observations, the top findings consistently include:

• Failure to follow written procedures (21 CFR 211.100)
• Inadequate laboratory controls
• Weak deviation handling

These are not theoretical lapses; they are the result of day-to-day operational breakdowns, when an SOP is misunderstood at a site, when a CAPA takes months to close due to disjointed approvals, or when critical risk data gets buried in disconnected systems.

Compliance is no longer a matter of strategy alone. It depends on execution, and that execution must be coordinated across functions, regions, and digital systems in real time.

So Where’s the Breakdown? In the Pharma Middle Office

To understand the source of these persistent breakdowns, one must look beyond the frontline shop floor or the executive boardroom. The real friction lies in the middle, in the overlooked layers of operations that connect strategic intent with day-to-day execution.

The Middle Office in pharma includes several key domains:

• Quality Assurance, where CAPA, deviation management, and audits are managed.
• Regulatory Affairs is responsible for global filings, change submission tracking, and responding to health authority queries.
• Clinical-to-Commercial Transitions, where tech transfer, scale-up, and validation occur.
• Audit and CAPA workflows, which require fast cross-functional coordination and data traceability.
• Change control, where any modification, from a process tweak to an API source change, must be risk-assessed, approved, and documented globally.

In a healthy Middle Office, these domains function like a connected mesh, responsive, visible, and synchronized. But in most pharma companies, they are isolated islands. The Quality team might be working on a standalone eQMS. Regulatory Affairs manages a separate tracking tool. Change control requests are emailed or managed in spreadsheets. Critical information is locked in PDFs, shared drives, or siloed databases that do not talk to each other.

This fragmentation leads to delays, blind spots, and ultimately, compliance risk. A CAPA might be marked “closed” in one system but still lack cross-functional verification. A process change may be implemented at one site but not reflected in global filings, triggering inconsistencies during inspections. The failure is not always visible until it results in a citation, product recall, or delayed market entry.

Pharma Compliance Systems Need to Work Together, Not in Silos

Over the last decade, pharma companies have adopted a wide range of best-in-class tools, including:

• eQMS for quality processes
• LIMS for lab data and test management
• ERP for enterprise resource planning
• RIM for regulatory information management
• MES for manufacturing execution

These platforms are individually validated, compliant, and effective, but rarely integrated. And that’s where the real problem begins.

Here’s what happens without integration:

• A quality deviation is logged in the eQMS
• The impacted batch record sits in the MES
• Any registration update goes into the RIM tool
• Teams work in isolation, duplicating efforts and missing context
• Manual coordination slows down communication and decision-making

This lack of connectedness is not just inefficient; it’s dangerous. It makes it hard to respond to inspection queries with confidence. It delays response times. It results in “closed” CAPAs that were never truly resolved. Worse, it creates a false sense of control.

According to a 2024 LNS Research study:

• Companies using integrated QMS/EHS platforms reported:

• 35% faster CAPA closure
• 25% fewer audit findings

Yet, the adoption gap remains:

• An ISPE survey revealed:

• 55% of pharma companies have embraced digital tools,
• Far fewer have taken the step to integrate them into a connected Middle Office

Envisioning the Connected Middle Office for Pharma

A truly connected Middle Office is more than a technical integration; it’s a structural shift in how pharma manages quality, compliance, and operational change. At its core, it enables shared context, real-time visibility, and closed-loop processes across quality, regulatory, manufacturing, and R&D.

Imagine a system where a deviation raised in MES automatically triggers a CAPA in the QMS, which then flags a potential impact on regulatory filings, instantly alerting RA teams to assess the change. All steps are logged, traceable, and auditable. Audit readiness becomes a continuous state, not a last-minute scramble. Risk assessments are standardized. Change approvals flow smoothly across global sites.

This is what a connected Middle Office delivers:

• Unified risk and compliance data across all systems.
• Real-time change control, with built-in impact assessments and audit trails.
• Smarter audit readiness, driven by live dashboards and automated documentation workflows.
• Closed-loop CAPA, tracking root cause, action, verification, and effectiveness checks in one place.
• Global harmonization, ensuring consistent processes and standards across regions, sites, and partners.

In short, it moves compliance from a reactive function to a proactive capability.

Why the Stakes Are Higher in Pharma

Pharma is held to a higher standard because the consequences of failure are immediate and severe:

• A minor lapse in process control or data integrity doesn’t just lead to rework. It can compromise patient safety, trigger regulatory enforcement, and disrupt global supply chains.
• The FDA performed 776 inspections in FY2023, up from 548 in FY2022. They issued 94 drug-quality Warning Letters, most of them to OTC or low-visibility manufacturers.
• Reputational damage from compliance failures can take years to repair. In a competitive global market, the difference between a trusted partner and a high-risk supplier hinges on how well the Middle Office functions.
• For pharma companies, the cost of inaction isn’t just financial; it’s existential. Compliance is no longer just a regulatory obligation; it’s a business imperative.

These stakes reinforce why the middle layer, where documents are reviewed, CAPAs are verified, and changes are executed, must be streamlined, auditable, and resilient.

Conclusion

For too long, pharma companies have focused their compliance energy on the endpoints, digitizing labs, upgrading shop-floor tools, and ticking regulatory boxes. But compliance doesn’t live at the edges. It lives in the messy, complex, day-to-day execution that happens in the Middle Office, where quality, regulatory, and operational teams are supposed to work in sync but operate in silos.

That’s beginning to change.

Forward-thinking pharma companies are realizing that audit readiness, regulatory responsiveness, and product quality are all Middle Office outcomes. And the companies that are winning? They’re the ones that treat their Middle Office not as a forgotten workflow layer but as a strategic hub of compliance execution and risk management.

This is where ComplianceQuest comes in.

As a Salesforce-native, AI-powered quality and compliance platform, ComplianceQuest is purpose-built to help pharma companies modernize their Middle Office. By unifying QMS, Regulatory, Supplier, and Training processes on a single, connected cloud platform, ComplianceQuest ensures that data doesn’t get buried, that CAPAs don’t go unresolved, and that compliance becomes a continuous, proactive process, not a fire drill before inspections.